Details of the Drug

General Information of Drug (ID: DMNMXR8)

• Drug Name: Procainamide
• Synonyms: Biocoryl; Novocainamid; Novocainamide; Novocamid; Procainamida; Procainamidum; Procamide; Procan; Procanbid; Procapan; Pronestyl; Novocaine amide; Procaine amide; P-Aminobenzoic diethylaminoethylamide; Procainamida [INN-Spanish]; Procainamide (INN); Procainamide [INN:BAN]; Procainamidum [INN-Latin]; Procan (TN); Procanbid (TN); Procapan (free base); Pronestyl (TN); Pronestyl-Sr; P-Amino-N-(2-diethylaminoethyl)benzamide; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-(9CI); 2-Diethylaminoethylamid kyseliny p-aminobenzoove; 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech]; 4-Amino-N-(2-(Diethylamino)Ethyl)Benzamide Sulfate; 4-Amino-N-(2-(diethylamino)ethyl)benzamide; 4-Amino-N-[2-(diethylamino)ethyl]benzamide; 4-amino-N-(2-diethylaminoethyl)-benzamide; 4-amino-N-(2-diethylaminoethyl)benzamide

Indication

Disease Entry	ICD 11	Status	REF
Ventricular arrhythmias	BC71	Approved	[1]

• Therapeutic Class: Antiarrhythmic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 235.33
  Logarithm of the Partition Coefficient (xlogp); 0.9
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  Absorption: The absorption of drug is 75 to 95% []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
  Bioavailability: 83% of drug becomes completely available to its intended biological destination(s) [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 10 mL/min/kg [4]
  Elimination: 67% of drug is excreted from urine in the unchanged form [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2.5 - 4.5 hours [4]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 212.46596 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.84% [4]
  Vd: The volume of distribution (Vd) of drug is 2 L/kg []
  Water Solubility: The ability of drug to dissolve in water is measured as 4 mg/mL [2]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Hepatotoxicity	Not Available	CYP2D6	OTZJC802	[6]
Sudden cardiac death	Not Available	KCNQ1	OT8SPJNX	[6]
Sudden cardiac death	Not Available	SCN5A	OTGYZWR6	[6]
Sudden cardiac death	Not Available	KCNE1	OTZNQUW9	[6]
Sudden cardiac death	Not Available	KCNH2	OTZX881H	[6]
Systemic lupus erythematosus	Not Available	NAA20	OTJB0VA6	[6]

• Chemical Identifiers:
  Formula: C13H21N3O
  IUPAC Name: 4-amino-N-[2-(diethylamino)ethyl]benzamide
  Canonical SMILES: CCN(CC)CCNC(=O)C1=CC=C(C=C1)N
  InChI: InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)
  InChIKey: REQCZEXYDRLIBE-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4913
  ChEBI ID: CHEBI:8428
  CAS Number: 51-06-9
  DrugBank ID: DB01035
  TTD ID: D0U5SI
  VARIDT ID: DR00292
  INTEDE ID: DR1343

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
E3 ubiquitin-protein ligase COP1 (RFWD2)	TT05DLS	COP1_HUMAN	Modulator	[7]
Voltage-gated sodium channel (Nav)	TTIG65Q	NOUNIPROTAC	Modulator	[7]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[8]
Multidrug and toxin extrusion protein 2 (SLC47A2)	DT3TX4H	S47A2_HUMAN	Substrate	[9]
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTZGT0P	S47A1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[10]
N-acetyltransferase 1 (NAT1)	DE7OAB3	ARY1_HUMAN	Substrate	[11]
RNA cytidine acetyltransferase (hALP)	DEZV4AP	NAT10_HUMAN	Substrate	[12]
N-acetyltransferase 2 (NAT2)	DER7TA0	ARY2_HUMAN	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Gene/Protein Processing	[14]
Arylamine N-acetyltransferase 1 (NAT1)	OTCCNQ3H	ARY1_HUMAN	Biotransformations	[15]
Arylamine N-acetyltransferase 2 (NAT2)	OTBPDQOY	ARY2_HUMAN	Biotransformations	[16]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Gene/Protein Processing	[17]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[6]
N-alpha-acetyltransferase 20 (NAA20)	OTJB0VA6	NAA20_HUMAN	Drug Response	[6]
Potassium voltage-gated channel subfamily E member 1 (KCNE1)	OTZNQUW9	KCNE1_HUMAN	Drug Response	[6]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Drug Response	[6]
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1)	OT8SPJNX	KCNQ1_HUMAN	Drug Response	[6]
Ras association domain-containing protein 1 (RASSF1)	OTEZIPB7	RASF1_HUMAN	Gene/Protein Processing	[17]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Procainamide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Procainamide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[18]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Procainamide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[19]

Coadministration of a Drug Treating the Disease Different from Procainamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Procainamide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[19]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Procainamide and Midostaurin.	Acute myeloid leukaemia [2A60]	[19]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Procainamide and Idarubicin.	Acute myeloid leukaemia [2A60]	[19]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Procainamide and Arn-509.	Acute myeloid leukaemia [2A60]	[19]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Procainamide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[19]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Procainamide and Oliceridine.	Acute pain [MG31]	[19]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Procainamide due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[20]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Procainamide due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[20]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Procainamide and Ivabradine.	Angina pectoris [BA40]	[20]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Procainamide and Bepridil.	Angina pectoris [BA40]	[21]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Procainamide and Dronedarone.	Angina pectoris [BA40]	[19]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Procainamide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[19]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Procainamide and Cilostazol.	Arterial occlusive disease [BD40]	[19]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Procainamide and Posaconazole.	Aspergillosis [1F20]	[19]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Procainamide and Levalbuterol.	Asthma [CA23]	[22]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Procainamide and Pirbuterol.	Asthma [CA23]	[23]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Procainamide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[19]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Procainamide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[19]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Procainamide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Procainamide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[19]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Procainamide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Procainamide and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Procainamide and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Procainamide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Procainamide and Retigabine.	Behcet disease [4A62]	[19]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Procainamide and Eribulin.	Breast cancer [2C60-2C6Y]	[19]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Procainamide and Lapatinib.	Breast cancer [2C60-2C6Y]	[19]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Procainamide and Bosutinib.	Breast cancer [2C60-2C6Y]	[19]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Procainamide when combined with Acetylcholine.	Cataract [9B10]	[26]
Iodipamide	DMXIQYS	Moderate	Increased risk of ventricular arrhythmias by the combination of Procainamide and Iodipamide.	Cholelithiasis [DC11]	[27]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Procainamide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[19]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Procainamide and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[28]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Procainamide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Procainamide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[22]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Procainamide and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[28]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Procainamide and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[28]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Procainamide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Procainamide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Isoproterenol	DMK7MEY	Major	Increased risk of ventricular arrhythmias by the combination of Procainamide and Isoproterenol.	Conduction disorder [BC63]	[23]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Procainamide and Atracurium.	Corneal disease [9A76-9A78]	[26]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Procainamide and Mivacurium.	Corneal disease [9A76-9A78]	[26]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Procainamide and Halothane.	Corneal disease [9A76-9A78]	[19]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Procainamide and Pancuronium.	Corneal disease [9A76-9A78]	[26]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Procainamide and Sevoflurane.	Corneal disease [9A76-9A78]	[19]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Procainamide and Probucol.	Coronary atherosclerosis [BA80]	[19]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Procainamide and Pasireotide.	Cushing syndrome [5A70]	[19]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Procainamide and Osilodrostat.	Cushing syndrome [5A70]	[19]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Procainamide and Sertraline.	Depression [6A70-6A7Z]	[19]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Procainamide and Escitalopram.	Depression [6A70-6A7Z]	[19]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Procainamide and Clomipramine.	Depression [6A70-6A7Z]	[19]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Procainamide and Doxepin.	Depression [6A70-6A7Z]	[19]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Procainamide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[19]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Procainamide and Deutetrabenazine.	Dystonic disorder [8A02]	[19]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Procainamide and Ingrezza.	Dystonic disorder [8A02]	[19]
Diphenhydramine	DMKQTBA	Moderate	Increased risk of prolong QT interval by the combination of Procainamide and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[29]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Procainamide and Solifenacin.	Functional bladder disorder [GC50]	[19]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Procainamide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[19]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Procainamide when combined with Pilocarpine.	Glaucoma [9C61]	[30]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Procainamide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Procainamide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Procainamide and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Procainamide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Procainamide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[32]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Procainamide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[19]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Procainamide and Crizotinib.	Lung cancer [2C25]	[19]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Procainamide and Ceritinib.	Lung cancer [2C25]	[19]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Procainamide and Osimertinib.	Lung cancer [2C25]	[19]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Procainamide and Selpercatinib.	Lung cancer [2C25]	[19]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Procainamide and Lumefantrine.	Malaria [1F40-1F45]	[29]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Procainamide and Halofantrine.	Malaria [1F40-1F45]	[33]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Procainamide and Hydroxychloroquine.	Malaria [1F40-1F45]	[19]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Procainamide and Primaquine.	Malaria [1F40-1F45]	[19]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Procainamide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[19]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Procainamide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[34]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Procainamide and Vemurafenib.	Melanoma [2C30]	[19]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Procainamide and LGX818.	Melanoma [2C30]	[19]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Procainamide and Panobinostat.	Multiple myeloma [2A83]	[19]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Procainamide and Thalidomide.	Multiple myeloma [2A83]	[29]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Procainamide and Siponimod.	Multiple sclerosis [8A40]	[29]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Procainamide and Ocrelizumab.	Multiple sclerosis [8A40]	[35]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Procainamide and Ozanimod.	Multiple sclerosis [8A40]	[19]
Neostigmine	DM6T2J3	Moderate	Antagonize the effect of Procainamide when combined with Neostigmine.	Myasthenia gravis [8C6Y]	[36]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Procainamide and Romidepsin.	Mycosis fungoides [2B01]	[19]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Procainamide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[19]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Procainamide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[19]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Procainamide and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[37]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Procainamide and Promethazine.	Nausea/vomiting [MD90]	[19]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Procainamide when combined with Metoclopramide.	Nausea/vomiting [MD90]	[38]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Procainamide and Entrectinib.	Non-small cell lung cancer [2C25]	[19]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Procainamide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[20]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Procainamide and Lofexidine.	Opioid use disorder [6C43]	[19]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Procainamide and Triclabendazole.	Parasitic worm infestation [1F90]	[19]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Procainamide and Pimavanserin.	Parkinsonism [8A00]	[19]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Procainamide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[39]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Procainamide and Lefamulin.	Pneumonia [CA40]	[40]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Procainamide and Degarelix.	Prostate cancer [2C82]	[19]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Procainamide and ABIRATERONE.	Prostate cancer [2C82]	[19]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Procainamide and Enzalutamide.	Prostate cancer [2C82]	[19]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Procainamide and Relugolix.	Prostate cancer [2C82]	[19]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Procainamide and Bicalutamide.	Prostate cancer [2C82]	[19]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Procainamide due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[20]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Procainamide due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[20]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Procainamide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[19]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Procainamide and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[25]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Procainamide due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[20]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Procainamide due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[20]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Procainamide due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[20]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Procainamide due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[20]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Procainamide due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[20]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Procainamide and Quetiapine.	Schizophrenia [6A20]	[19]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Procainamide and Aripiprazole.	Schizophrenia [6A20]	[29]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Procainamide and Iloperidone.	Schizophrenia [6A20]	[19]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Procainamide and Paliperidone.	Schizophrenia [6A20]	[19]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Procainamide and Amisulpride.	Schizophrenia [6A20]	[19]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Procainamide and Asenapine.	Schizophrenia [6A20]	[19]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Procainamide and Pimozide.	Schizophrenia [6A20]	[20]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Procainamide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[19]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Procainamide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[41]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Procainamide and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[19]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Procainamide and Pitolisant.	Somnolence [MG42]	[19]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Procainamide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[19]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Procainamide and Lenvatinib.	Thyroid cancer [2D10]	[19]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Procainamide and Cabozantinib.	Thyroid cancer [2D10]	[19]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Procainamide and Papaverine.	Tonus and reflex abnormality [MB47]	[42]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Procainamide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[19]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Procainamide and Valganciclovir.	Virus infection [1A24-1D9Z]	[29]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4811).
• [2] BDDCS applied to over 900 drugs
• [3] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
• [9] Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
• [10] Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics. 1999 Dec;9(6):683-96.
• [11] Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine. Biochem Pharmacol. 1996 Nov 22;52(10):1613-20.
• [12] Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
• [13] Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol. 2000 Mar;57(3):468-73.
• [14] Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest. 2004 Oct;114(8):1146-57.
• [15] Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. Protein J. 2005 Feb;24(2):65-77.
• [16] Interindividual variability in 5-Fluorouracil metabolism and procainamide N-acetylation in human liver cytosol. Biol Pharm Bull. 2005 Jun;28(6):1071-4. doi: 10.1248/bpb.28.1071.
• [17] Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase. Environ Health Perspect. 2007 Oct;115(10):1454-9. doi: 10.1289/ehp.10207.
• [18] Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]
• [19] Canadian Pharmacists Association.
• [20] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [21] Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
• [22] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [23] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [24] Martin DE, Shen J, Griener J, Raasch R, Patterson JH, Cascio W "Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide." J Clin Pharmacol 36 (1996): 85-91. [PMID: 8932548]
• [25] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [26] Multum Information Services, Inc. Expert Review Panel.
• [27] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98. [PMID: 15206999]
• [28] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [29] Cerner Multum, Inc. "Australian Product Information.".
• [30] Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
• [31] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [32] Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
• [33] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [34] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [35] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [36] Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
• [37] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [38] Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
• [39] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [40] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [41] Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [42] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]